I'd call that loose journalistic language rather than an actual mistake.
This is the offending sentence I was complaining about:
And thus four drug makers — Amgen, Eli Lilly, Teva Pharmaceuticals, and Alder Biopharmaceuticals — have fashioned antibodies that can bind to CGRP molecules and block their activity.
Only three of these molecules actually bind to CGRP - Amgen has a mab that binds to the CGRP receptor.
I might speculate that in theory that approach might produce longer duration (because no target-mediated destruction of the drug), but no evidence I know of that that has actually turned out to be the case.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.